Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

Qyuns Therapeutics Co Ltd (2509ta)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
20.64 0.00    0.00%
11/08 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  CNE1000069W9 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 19.53 - 20.74
Qyuns Therapeutics 20.64 0.00 0.00%

Qyuns Therapeutics Co Ltd Company Profile

 
Get an in-depth profile of Qyuns Therapeutics Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

339

Equity Type

ORD

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which is in Phase III clinical trial for the treatment of prurigo nodularis. The company also commercializes QX001S, which is an IL-12/L-23p49 inhibitor for psoriasis under the SAILEXIN brand. In addition, it develops, manufactures, and commercializes QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD; QX004N, an IL-23p19 inhibitor in Phase II clinical trial to treat psoriasis and Crohn’s disease; QX013N, a humanized IgG1 mAb targeting c-kit; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial for the treatment of systemic lupus erythematosus; QX007N, a humanized IgG1 mAb targeting IL-33 for the treatment of moderate-to-severe COPD and asthma; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.

Contact Information

Address Building 1 Room 1310
No. 907 Yaocheng Avenue Taizhou,
China
Phone 86 523 8027 6311
Fax -

Top Executives

Name Age Since Title
Xiang Ye 51 2021 Independent President of the Supervisor
Jianqun Ling 55 2024 Independent Non-Executive Director
Che Wai Fung 55 2024 Independent Non-Executive Director
Chao Ding 36 2022 Independent Supervisor
Zhongmei Zou 59 2024 Independent Non-Executive Director
Yujiao Wang 42 2021 Employee Representative Supervisor
Yiliang Wu 43 2019 Executive Director & Executive Deputy GM of Cellularforce
Jiwan Qiu 52 2015 GM & Chairman of the Board
Weidong Lin 42 2021 Deputy GM & Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2509ta Comments

Write your thoughts about Qyuns Therapeutics Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email